209,882 Shares in Accuray Incorporated (NASDAQ:ARAY) Purchased by Mackay Shields LLC

Mackay Shields LLC acquired a new stake in Accuray Incorporated (NASDAQ:ARAY) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 209,882 shares of the medical equipment provider’s stock, valued at approximately $715,000. Mackay Shields LLC owned 0.24% of Accuray at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its stake in Accuray by 8.6% during the third quarter. Renaissance Technologies LLC now owns 5,312,623 shares of the medical equipment provider’s stock worth $23,907,000 after buying an additional 422,023 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Accuray by 3.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,321,330 shares of the medical equipment provider’s stock worth $7,916,000 after purchasing an additional 78,330 shares in the last quarter. Vident Investment Advisory LLC lifted its position in shares of Accuray by 2.3% during the third quarter. Vident Investment Advisory LLC now owns 2,233,056 shares of the medical equipment provider’s stock worth $10,049,000 after purchasing an additional 49,156 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Accuray by 3,259.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,162,567 shares of the medical equipment provider’s stock worth $9,732,000 after purchasing an additional 2,098,187 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Accuray by 9.6% during the third quarter. Legal & General Group Plc now owns 1,366,100 shares of the medical equipment provider’s stock worth $6,147,000 after purchasing an additional 119,149 shares in the last quarter. 80.24% of the stock is owned by hedge funds and other institutional investors.

Several analysts have recently issued reports on ARAY shares. Zacks Investment Research cut shares of Accuray from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. BidaskClub raised shares of Accuray from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 10th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. Accuray has a consensus rating of “Hold” and an average target price of $5.13.

In related news, CEO Joshua Levine sold 6,604 shares of the firm’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $4.54, for a total value of $29,982.16. Following the sale, the chief executive officer now owns 1,033,593 shares of the company’s stock, valued at $4,692,512.22. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 3.40% of the stock is owned by company insiders.

Shares of ARAY traded up $0.09 during mid-day trading on Friday, hitting $4.10. 630,742 shares of the company’s stock were exchanged, compared to its average volume of 605,463. The stock has a market capitalization of $360.31 million, a PE ratio of -14.64 and a beta of 2.07. Accuray Incorporated has a fifty-two week low of $3.16 and a fifty-two week high of $5.40. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.00 and a current ratio of 1.71.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings results on Tuesday, January 22nd. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.03. The business had revenue of $102.32 million for the quarter, compared to analysts’ expectations of $104.01 million. Accuray had a negative net margin of 5.74% and a negative return on equity of 42.74%. During the same quarter in the prior year, the company earned ($0.06) earnings per share. On average, sell-side analysts predict that Accuray Incorporated will post -0.16 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.baseballdailydigest.com/news/2019/04/21/209882-shares-in-accuray-incorporated-aray-purchased-by-mackay-shields-llc.html.

Accuray Profile

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

Recommended Story: What are municipal bonds?

Institutional Ownership by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.